Skip to content

Construction and Verification of Acupoint Injected by Ozone Therapy in Knee Osteoarthritis :A Mixed Methods

Construction and Verification of Acupoint Injected by Ozone Therapy in Knee Osteoarthritis :A Mixed Methods

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300073926
Enrollment
Unknown
Registered
2023-07-25
Start date
2023-08-01
Completion date
Unknown
Last updated
2023-07-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee Osteoarthritis

Interventions

Ozone acupoint injection group:Ozone acupoint injection

Sponsors

Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Compliant with KOA diagnostic criteria; (2) Age 40–75 years old; (3) Kellgren-Lawrence Grade II or III; (4) The average NRS score of the knee joint in the past week = 4; (5) Pain occurs for more than three months; (6) Sign the informed consent form and participate in the research voluntarily.

Exclusion criteria

Exclusion criteria: (1) the knee joint with pain to be treated as a history of knee joint replacement or is in the waiting period for knee joint surgery; (2) knee osteoarthritis is secondary to rheumatoid arthritis, gouty arthritis, psoriatic arthritis, and hemophilia arthritis. (3) other diseases that may affect knee osteoarthritis include psoriasis, acute trauma, syphilis, and diabetes. (4) pain or dysfunction of lower limbs caused by non-knee joint diseases; (5) those whose skin was damaged, ulcerated, or locally infected, has a history of bleeding tendency or clinical manifestations (including those who are currently using anticoagulants) and are not suitable for acupuncture; (6) being treated with acupuncture and moxibustion in the past three months; (7) suffering from a severe acute or chronic organic disease or mental illness, blood coagulation disorder, previous pacemaker installation, metal allergy, or needle history; (8) pregnancy or breastfeeding; (9) observers who may affect the effective index of this study after receiving other related treatments; (10) glucose -6- phosphate dehydrogenase (G-6-PD) defect; (11) having been treated with copper or iron.

Design outcomes

Primary

MeasureTime frame
Pain Numerical Rating Scale;

Secondary

MeasureTime frame
Western Ontario and McMaster Universities Arthritis Index;Patient Global Assessment;Life Quality Evaluation;NRS Response Rate;

Countries

China

Contacts

Public Contactnijinxia

Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine

nijinxia118@126.com+86 152 1081 6781

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026